NCT00565097

Lanreotide as Treatment of Polycystic Livers

Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 38 (estimated)
• Sponsor: Radboud University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 88 Years
• Healthy volunteers: Not accepted

Summary

To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed. A minimum of 38 patients will be recruited and randomized (1:1) to receive either verum or placebo. Lanreotide is already used in other disease states and found to be safe and non-toxic.

Conditions

• Polycystic Liver Disease
• Hepatomegaly
• Liver Diseases
• Polycystic Kidney, Autosomal Dominant

Interventions

Type	Name	Description
DRUG	Placebo
DRUG	Lanreotide

Timeline

• Start date: 2007-10-01
• First posted: 2007-11-29
• Last updated: 2009-02-17

Locations

2 sites across 2 countries: Belgium, Netherlands